IDH1 and neoplasm: Of the 28 patients who underwent tumor progression, 12 (42.9%) patients (including 4 IDH-wt LTS and 8 IDH-mut LTS) received re-operation, 15 (53.6%) patients (including 5 IDH-wt LTS and 10 IDH-mut LTS) received reirradiation, and all (100.0%) patients (including 8 IDH-wt LTS and 20 IDH-mut LTS) received rechallenge with chemotherapy (Figure S2).